UPDATED: Kardigan buttons up $400M upsized IPO to power heart drugs toward phase 3 on June 18, 2026 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide Cardiovascular system IPO Kardigan Nasdaq KARD tonlamarsen +
Kardigan’s $320M IPO pitch: Three borrowed heart drugs, one proven cardio CEO on June 12, 2026 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide Cardiovascular system IPO Kardigan methionine Myers Squibb MyoKardia Nasdaq KARD sanofi Tassos Gianakakos tonlamarsen +
Kardigan readies Nasdaq IPO to back three cardio drugs – latest news summary on May 28, 2026 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide Cardiovascular Agents cardiovascular program diluted cardiomyopathy IPO KARD Kardigan Nasdaq tonlamarsen +
Kardigan files for IPO to fund late‑stage cardiovascular pipeline on May 27, 2026 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide calcific aortic valve stenosis genetic dilated cardiomyopathy IPO Jefferies Kardigan Nasdaq KARD tonlamarsen +